Email the author Risk Factors for EGFR (Epidermal Growth Factor Receptor) Gene Mutations in Lung Adenocarcinoma Patients at Arifin Achmad Hospital, Riau Province
Abstract
Background: Lung cancer is the first cause of oncological death worldwide. Guidelines made by various cancer associations, including PDPI-IASTO, regarding NSCLC recommend that all advanced stages of NSCLC undergo target genetic testing, such as EGFR mutations. The incidence of EGFR mutations in Asian populations is quite high.
Methods: This was a retrospective observational analytic study with a cross-sectional study design.
Results: The most unmodifiable risk factors were age ≥45 years (81.4%), male sex (70.6%), location of lung cancer on the right (52.9%), cancer size of ≥5 cm (100%), M1a metastases (57.8%), and no family history of malignancy (97.1%). The smoking status (ex-smoker) (P=0.022; OR=4.3; 95% CI=1.24-15.57), sex (male) (P=0.007; OR=3.409; 95% CI=1.406-8.268), and metastatic status (M1a) (P=0.025; OR=0.203; 95% CI=0.05-0.821) were the dominant risk factors that affected the incidence of EGFR mutations in patients with lung adenocarcinoma at Arifin Achmad Hospital.
Conclusion: Male, ex-smokers, and metastatic status (M1a) were the dominant risk factors for the incidence of EGFR mutations in lung adenocarcinoma patients at Arifin Achmad Hospital.
Keywords
Full Text:
PDFReferences
Hudoyo A, Yahya WS, Andarini SL, Jusuf A. Terapi target untuk kanker paru. In: Seri buku ajar onkologi toraks – Pengobatan kanker paru. Jakarta: Departemen Pulmonologi dan Kedokteran Respirasi FKUI; 2019. p. 66–7.
Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. J Clin Oncol. 2013;31(8):1039–49.
Malik PS, Jain D, Kumar L. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncology. 2016;91 Suppl 1:26–34.
Abubakar MB, Gan SH. Molecular targets in advanced therapeutics of cancers: The role of pharmacogenetics. Oncology. 2016;91(1):3–12.
Zhang H, Cai W, Wang Y, Liao M, Tian S. CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2019;24(6):649–59.
Jusuf A, Wibawanto A, Icksan AG, Syahruddin E, Juniarti, Endarjo S. Kanker paru jenis karsinoma bukan sel kecil pedoman diagnosis dan penatalaksanaan di Indonesia. PDPI-IASTO: UI Press; 2018.
Tomonaga N, Nakamura Y, Yamaguchi H, Ikeda T, Mizoguchi K, Motoshima K, et al. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin Lung Cancer. 2013;14(5):521–6.
Herbst RS, Heymach J V, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80.
Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179–86.
Chen YM. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. J Chin Med Assoc. 2013;76(5):249–57.
Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016;10(2):113–29.
Tang ER, Schreiner AM, Pua BB. Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS). J Thorac Dis. 2014;6 (Suppl 5):S489–501
Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006;11(3):190–8.
Igawa S, Sasaki J, Otani S, Shirasawa M, Niwa H, Kusuhara S, et al. Smoking history as a predictor of pemetrexed monotherapy in patients with non-squamous non-small cell lung cancer. Oncology. 2016;91(1):41–7.
Aunan JR, Cho WC, Søreide K. The biology of aging and cancer: A brief overview of shared and divergent molecular hallmarks. Aging Dis. 2017;8(5):628–42.
Ortiz AFH, Camacho TC, Vásquez AF, del Castillo Herazo V, Neira JGA, Yepes MM, et al. Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis. Eur J Radiol Open. 2022;9:100400.
Shi Y, Au JSK, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–62.
Elhidsi M, Andarini SL, Hudoyo A. Profil mutasi epidermal growth factor receptor pasien adenokarsinoma paru usia muda. J Respirol Indones. 2016;36(4):5.
Syahruddin E, Wulandari L, Sri Muktiati N, Rima A, Soeroso N, Ermayanti S, et al. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. Lung Cancer (Auckl). 2018;9:25–34.
Wu SG, Chang YL, Yu CJ, Yang PC, Shih JY. Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Res. 2017;3(3):92–2016.
Xia J, Li H, Ji Y, Mi C, Chen G, Li P, et al. Clinicopathologic characteristics and EGFR mutations in lung cancer patients aged below 45 years. Curr Probl Cancer. 2019;43(4):363–70.
Choi W Il, Jeong J, Lee CW. Association between EGFR mutation and ageing, history of pneumonia and gastroesophageal reflux disease among patients with advanced lung cancer. Eur J Cancer. 2019;122:101–8.
Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. Br J Cancer. 2020;122(7):943–52.
Liu Q, Sun D, Li N, Kim J, Feng D, Huang G, et al. Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features. Transl Lung Cancer Res. 2020;9(3):549–62.
Leal LF, de Paula FE, De Marchi P, de Souza Viana L, Pinto GDJ, Carlos CD, et al. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations. Sci Rep. 2019;9(1):1–10.
Pi C, Xu CR, Zhang M feng, Peng X xiao, Wei X wu, Gao X, et al. EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. Thorac Cancer. 2018;814–9.
Zhou X, Cai L, Liu J, Hua X, Zhang Y, Zhao H, et al. Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma. Oncol Lett. 2018;16(1):362–70.
Stapelfeld C, Dammann C, Institute EM. Sex-specificity in lung cancer risk IJC. Intenational J Cancer. 2020;146:2376–82.
Kim JS, Cho MS, Nam JH, Kim HJ, Choi KW, Ryu JS. Prognostic impact of EGFR mutation in nonsmall-cell lung cancer patients with family history of lung cancer. PLoS ONE. 2017;12(5):1–9.
Cheng YI, Gan YC, Liu D, Davies MPA, Li WM, Field JK. Potential genetic modifiers for somatic EGFR mutation in lung cancer: A meta-Analysis and literature review. BMC Cancer. 2019;19(1):1068.
Nazir M, Hayatinur E, Jajuli A. Profil kesehatan Provinsi Riau Tahun 2020. Dinas Kesehatan Provinsi Riau. Pekanbaru; 2021. 16–155 p.
Calibasi-Kocal G, Amirfallah A, Sever T, Unal OU, Gurel D, Oztop I, et al. EGFR mutation status in a series of Turkish non-small cell lung cancer patients. Biomed Reports. 2020;13(2):1–9.
Chen Y mu, Lai C hao, Lin C yu, Tsai Y hsuan, Chang Y chun, Chen H chen, et al. Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation. Nutrients. 2021;13:1–13.
Esteban E, Majem M, Martinez Aguillo M, Martinez Banaclocha N, Dómine M, Gómez Aldaravi L, et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiol. 2015;39(3):291–7.
Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Prim. 2021;7(1).
Lou W, Liu J, Gao Y, Zhong G, Chen D, Shen J, et al. MicroRNAs in cancer metastasis and angiogenesis. Oncotarget. 2017;8(70):115787–802.
Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35(1):75–91.
Butler LM, Perone Y, Dehairs J, Lupien LE, de Laat V, Talebi A, et al. Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020;159:245–93.
Alifano M, Daffré E, Iannelli A, Brouchet L, Falcoz PE, Barthes FLP, et al. The reality of lung cancer paradox: The impact of body mass index on long-term survival of resected lung cancer. a french nationwide analysis from the epithor database. Cancers (Basel). 2021;13(18):4574.
Jiang M, Fares AF, Shepshelovich D, Yang P, Christiani D, Zhang J, et al. The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. Lung Cancer. 2021;152:58–65.
Yuen EYN, Zaleta AK, McManus S, Buzaglo JS, LeBlanc TW, Hamilton K, et al. Correction to: Unintentional weight loss, its associated burden, and perceived weight status in people with cancer. Support Care Cancer. 2022;30(9):7813.
Jia TY, Xiong JF, Li XY, Yu W, Xu ZY, Cai XW, et al. Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. Eur Radiol. 2019;29(9):4742–50.
Prameswari YN, Dwi Anita Suryandari. Correlation Epidermal Growth Factor Receptor Mutation with Non-small Cell Lung Cancer in Passive Smokers: A Review. Biosci Medi : J Biomed Transl Res. 2022;6(4):1624–35.
Zhou Y, Ge F, Du Y, Li Q, Cai J, Liu X, et al. Unique profile of driver gene mutations in patients with non-small-cell lung cancer in Qujing City, Yunnan Province, Southwest China. Front Oncol. 2021;11:1–10.
Riza NM, Maranatha D. Triple mutation epidermal growth factor receptor EGFR exon 18 G719S, 20 T790M and 21 L858R in a male patient with lung adenocarcinoma: A case report. J Respirasi. 2020;6(1):13–20
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: Results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol. 2017;28(11):2715–24.
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–93.
Mei D, Luo Y, Wang Y, Gong J. CT texture analysis of lung adenocarcinoma: Can radiomic features be surrogate biomarkers for EGFR mutation statuses. Cancer Imaging. 2018;18(1):1–9.
Hong D, Xu K, Zhang L, Wan X, Guo Y. Radiomics signature as a predictive factor for egfr mutations in advanced lung adenocarcinoma. Front Oncol. 2020;10:1–8.
Wang S, Shi J, Ye Z, Dong D, Yu D, Zhou M, et al. Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning. Eur Respir J. 2019;53(3):1800986.
Sahoo R, V VH, Babu VC, V. Patil Okaly G, Rao S, Nargund A, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer. 2011;73(3):316–9.
Benbrahim Z, Antonia T, Mellas N. EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis. BMC cancer. 2018;18(1):891.
Russo A, Franchina T, Ricciardi GRR, Fanizza C, Scimone A, Chiofalo G, et al. Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer. Oncotarget. 2017;8(5):8717–25.
Tseng C hua, Chiang C ju, Tseng J sen, Yang T ying. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017;8(58):98384–93.
Honda T, Sakashita H, Masai K, Totsuka H, Motoi N, Kobayashi M, et al. Deleterious pulmonary surfactant system gene mutations in lung adenocarcinomas associated with usual interstitial pneumonia. JCO Precis Oncol. 2018;(2):1–24.
Li WY, Zhao TT, Xu HM, Wang ZN, Xu YY, Han Y, et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: A systematic review and meta-analysis. BMC Cancer. 2019;19(1):1–9.
Guan J, Chen M, Xiao N, Li L, Zhang Y, Li Q, et al. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan. Med Oncol. 2016;33(1):1–5.
Li L, Luo S, Lin H, Yang H, Chen H, Liao Z, et al. Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer. J Thorac Dis. 2017;9(8):2510–20.
Kit OI, Vodolazhsky DI, Timoshkina NN, Yu Vladimirova L, Turkin IN, Kutsyn KA, et al. EGFR mutations and tumor metastases in patients with non-small cell lung cancer in the South of Russia. J BUON. 2017;22(6):1410–5.
Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016;102:122–34.
Han G, Bi J, Tan W, Wei X, Wang X, Ying X, et al. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: Is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget. 2016;7(35):56998–7010.
DOI: https://doi.org/10.36497/jri.v44i3.484
Refbacks
- There are currently no refbacks.
Copyright (c) 2024 Bayu Aulia Riensya, Sri Melati Munir, Dewi Wijaya
INDEXING & PARTNER
| Jurnal Respirologi Indonesia pISSN: 0853-7704 - eISSN: 2620-3162 Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia Phone: +62-21-2247-4845 Email: editor@jurnalrespirologi.org |  An official publication by the Indonesian Society of Respirology (ISR) |
 Creative Commons Attribution-ShareAlike 4.0 International License Statcounter |